| Ocular Hypertension
Combigan vs Lumigan
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Combigan vs Lumigan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLumigan has a higher rate of injection site reactions vs Combigan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lumigan but not Combigan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Combigan
Lumigan
At A Glance
Topical (ophthalmic)
Twice daily
Alpha-2 agonist / beta-blocker
Ophthalmic
Once daily
Prostaglandin analog
Indications
- Glaucoma
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Ocular Hypertension One drop in the affected eye(s) twice daily approximately 12 hours apart; if using multiple topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle; Ocular Hypertension One drop in the affected eye(s) once daily in the evening; if used concomitantly with other topical ophthalmic drugs, administer at least 5 minutes apart.
Contraindications
- Bronchial asthma, history of bronchial asthma, or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
- Neonates and infants (pediatric patients younger than 2 years old)
- Hypersensitivity to any component of this product
- Hypersensitivity to bimatoprost or any excipient
Adverse Reactions
Most common (5%-15%) allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, stinging
Serious hypersensitivity reactions, severe respiratory or cardiac reactions, cardiac failure, potentiation of vascular insufficiency, increased reactivity to allergens, potentiation of muscle weakness, masking of hypoglycemia, masking of thyrotoxicosis, ocular hypersensitivity
Postmarketing bradycardia, eyelid erythema, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=1%) Conjunctival hyperemia, conjunctival edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, erythema of eyelid, eyelid pruritus, growth of eyelashes, hypertrichosis, instillation site irritation, punctate keratitis, skin hyperpigmentation, blurred vision, reduced visual acuity
Postmarketing Asthma-like symptoms, dizziness, dry eye, dyspnea, eye discharge, eye edema, foreign body sensation, headache, hypersensitivity, hypertension, increased lacrimation, periorbital and lid changes, photophobia
Pharmacology
COMBIGAN combines brimonidine tartrate, a relatively selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow, with timolol maleate, a non-selective beta-1 and beta-2 adrenergic receptor inhibitor, to lower elevated intraocular pressure.
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes, selectively mimicking naturally occurring prostamides.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Combigan
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Lumigan
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Combigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Lumigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Combigan
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Lumigan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Combigan.
No savings programs available for Lumigan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CombiganView full Combigan profile
LumiganView full Lumigan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.